OncoMatch/Clinical Trials/NCT06114082
TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma
Is NCT06114082 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for hepatocellular carcinoma.
Little is known about whether the types of chemotherapeutic agents affect the efficacy of transarterial chemoembolization in patients with hepatocellular carcinoma. Although doxorubicin is the most commonly-used chemotherapeutic agent in the world, idarubicin is recently in the spotlight after promising results of the in vitro and prospective single-arm studies. On the other hand, there are many reports showing that the type of chemotherapeutic agents does not significantly alter the efficacy of transarterial chemoembolization. This is a randomized-controlled trial to show the non-inferiority of idarubicin compared to doxorubicin in patients with hepatocellular carcinoma who receive transarterial chemoembolization as the first-line treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
WBC count ≤ 12,000 / mm3; Absolute neutrophil count ≥ 1,500 /mm3; Hemoglobin ≥ 8.0 g/dL
Kidney function
eGFR ≥ 30 mL/min/1.73 m2
Liver function
Total bilirubin ≤ 3.0 mg/dL; Child-Pugh class A or B
Cardiac function
No severe heart failure or arrhythmia
Patients without severe functional abnormalities of major organs: ... WBC count ≤ 12,000 / mm3; Absolute neutrophil count ≥ 1,500 /mm3; Hemoglobin ≥ 8.0 g/dL; Total bilirubin ≤ 3.0 mg/dL; eGFR ≥ 30 mL/min/1.73 m2; Child-Pugh class A or B; severe heart failure, arrhythmia [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify